- A. Health Biotechnology
- Areas of activity
- Therapeutic areas
- D. Services
- Professional services
- CRO / CMO / SMO
PharmaMar, founded in 1986, is a biopharmaceutical company which explores the seas to find innovative antitumorals treatments. PharmaMar is conducting a pioneering marine biotechnology programme in search of new marine-based drugs. The company's research taps the sea, whose enormous biodiversity makes it a model for discovering new anti-tumour drugs.
PharmaMar currently has six compounds under clinical development for different indications. The sea´s potential as a source of medicines was confirmed with the 2007 approval of the first marine-based antitumoral; PharmaMar obtained marketing authorisation for the treatment of advanced soft tissue sarcoma in adults throughout the EU and Switzerland, and also in countries where our partners undertake development and commercialisation. In 2009, the drug was approved by the European Comission for platinum-sensitive relapsed ovarian cancer.
Our business strategy is to find co-development partners who are able to successfully contribute to a joint development. To this end, we seek partners who can contribute to successfully develop our product portfolio of marine origin in Europe, USA and Japan. PharmaMar retains commercialization rights for Europe while granting licenses for all territories outside of Europe.